HT
RPRX icon

Headlands Technologies’s Royalty Pharma RPRX Stock Holding History

Headlands Technologies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09M Buy
+90,729
New +$4.72M 0.54% 35
2025
Q1 		– Sell
-4,489
Closed -$115K – 1463
2024
Q4 		$115K Sell
4,489
-33,066
-88% -$877K 0.01% 638
2024
Q3 		$1.06M Buy
37,555
+37,341
+17,449% +$1.03M 0.12% 183
2024
Q2 		$5.64K Sell
214
-19,508
-99% -$541K ﹤0.01% 1012
2024
Q1 		$599K Sell
19,722
-3,363
-15% -$99.1K 0.14% 168
2023
Q4 		$648K Sell
23,085
-493
-2% -$13.5K 0.19% 111
2023
Q3 		$640K Buy
+23,578
New +$700K 0.31% 76

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's RPRX Position: Q2 2026 in Review

Headlands Technologies opened a new position in Royalty Pharma (RPRX) in Q2 2026: 90,729 shares worth $5.09M. The stake represents 0.54% of the portfolio and ranks #35 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in RPRX as recently as Q4 2024.

Headlands Technologies first reported a position in RPRX in Q3 2023 and has held it in 7 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Headlands Technologies held 90,729 shares of Royalty Pharma worth $5.09M as of Q2 2026.
  • Royalty Pharma was a new Headlands Technologies position in Q2 2026.
  • Royalty Pharma made up 0.54% of Headlands Technologies's portfolio in Q2 2026, its #35 holding.
  • Headlands Technologies first reported a position in Royalty Pharma in Q3 2023 and has held it in 7 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.